Monoclonal antibody · developed by Kiniksa Pharmaceuticals
Abiprubart (KPL-404) is a humanized monoclonal antibody. It is studied in rheumatoid arthritis and Sjögren's disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06531395 | Phase 2 | Sjögrens Disease | Terminated | KNSA |
| NCT05198310 | Phase 2 | Arthritis, Rheumatoid | Completed | KNSA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Arthritis, RheumatoidSjögrens Disease
Updated Oct 18, 2026. Something wrong or missing? Report it on the KNSA page.
See KNSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KNSA catalysts and pipeline →